Stemline Therapeutics Inc (NASDAQ:STML) CAO David Gionco sold 13,492 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $11.11, for a total value of $149,896.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

David Gionco also recently made the following trade(s):

  • On Thursday, March 7th, David Gionco sold 1,381 shares of Stemline Therapeutics stock. The stock was sold at an average price of $11.32, for a total value of $15,632.92.
  • On Monday, February 25th, David Gionco sold 8,563 shares of Stemline Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $103,012.89.

Stemline Therapeutics stock opened at $13.62 on Friday. The company has a market cap of $433.13 million, a PE ratio of -4.63 and a beta of 1.12. Stemline Therapeutics Inc has a 52 week low of $7.82 and a 52 week high of $20.55.

A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. Piper Jaffray Companies restated an “overweight” rating on shares of Stemline Therapeutics in a report on Wednesday, February 6th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Stemline Therapeutics in a report on Friday, January 25th. ValuEngine cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. Finally, BidaskClub upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, December 27th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $25.40.

Several institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc boosted its stake in shares of Stemline Therapeutics by 27.1% during the 4th quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 1,120 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Stemline Therapeutics by 11.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 29,723 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 2,982 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Stemline Therapeutics by 56.8% during the 4th quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 3,866 shares during the last quarter. Great West Life Assurance Co. Can purchased a new position in shares of Stemline Therapeutics during the 4th quarter valued at approximately $47,000. Finally, MetLife Investment Advisors LLC boosted its stake in shares of Stemline Therapeutics by 54.6% during the 3rd quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 6,527 shares during the last quarter. Institutional investors own 64.82% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “David Gionco Sells 13,492 Shares of Stemline Therapeutics Inc (STML) Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/david-gionco-sells-13492-shares-of-stemline-therapeutics-inc-stml-stock/2896817.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Featured Article: How Do You Calculate Return on Investment (ROI)?

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.